← Leaderboards
Kyle James Gontjes
University Of Michigan At Ann Arbor
$84,318
Attributed
$84,318
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $42.7K · FY2024–25$50K$37.5K$25K$12.5K$0
'24
'25
Funding mix
By agency
NIH$84,318 · 1
By mechanism
F31$84,318 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Evan Snitkin$6,188,096
- John D Birkmeyer$4,963,961
- Robert J Woods$3,831,487
- Gail M Keenan$2,527,879
- Scott Ellis Regenbogen$941,550
Others in their field
Other Rising Stars on “Admission Activity”
- John Alam · Eip Pharma, Inc.$10,536,018
- Gary Lessing · Inovodel, Inc.$2,946,822
- Lorraine I Kelley-Quon · Children'S Hospital Of Los Angeles$2,495,528
- Joseph Shapiro · National Bureau Of Economic Research$2,440,931
- Katherine Hoops · Johns Hopkins University$2,401,338
- Timothy William Dunn · Duke University$2,387,866
Research focus
Admission ActivityAntibiotic ResistanceAntibiotic-Resistant OrganismAntibioticsAntibiotic SusceptibilityBacteriaBacterial GeneticsBeta-LactamaseBeta-Lactam ResistanceBeta-LactamsBioinformaticsCaliforniaCarbapenem ResistanceCarbapenemsCareerCase/Control StudiesCategoriesCharacteristicsClinical DataClinical PracticeClonal ExpansionCollectionCombatAcute Care
Grant awards (2)
Genome-driven identification of patient and bacterial drivers of resistance to novel beta-lactam/beta-lactamase inhibitor combination therapies$42,663
F31 · FY2025 · AI · contact PI
Genome-driven identification of patient and bacterial drivers of resistance to novel beta-lactam/beta-lactamase inhibitor combination therapies$41,655
F31 · FY2024 · AI · contact PI